SYDNEY, Feb. 16 Pharmaceutical company Pharmaxis(ASX: PXS; Nasdaq: PXSL) today announced that it had appointed Dr Howard Foxto its senior management team in the position of Chief Medical Officer. DrFox will assume responsibility for regulatory affairs, pharmacovigilance andmedical affairs. Clinical Operations will continue to report to the MedicalDirector, Dr Brett Charlton.
Dr Fox has more than 15 years experience in the internationalpharmaceutical industry, the last ten of which has been in respiratory productdevelopment. He was most recently with Novartis as a Global Brand MedicalDirector and previously held the positions of Senior Clinical ResearchPhysician and Principle Medical Expert for Novartis.
Dr Alan Robertson, Pharmaxis Chief Executive Officer said: "Theappointment of Howard Fox provides the international regulatory andpharmacovigilance experience necessary for Pharmaxis to bring Bronchitolsuccessfully and rapidly to the market and we are very much looking forward tohis contribution."
Dr Fox who has just relocated from the United Kingdom will be based at thecompany's head office in Sydney.
Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical companyinvolved in the research, development and commercialization of therapeuticproducts for chronic respiratory and immune disorders. Its developmentpipeline of products includes Aridol for the management of asthma, Bronchitolfor cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease(COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma.Founded in 1998, Pharmaxis is listed on the Australian Securities Exchange(symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company isheadquartered in Sydney at its TGA-approved manufacturing facilities. For moreinformation about Pharmaxis, go to http://www.pharmaxis.com.au or contactInvestor Relations on phone +61 2 9454 7200.
The statements contained in this media release that are not purelyhistorical are forward-looking statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended. Forward-looking statements inthis media release include statements regarding our expectations, beliefs,hopes, goals, intentions, initiatives or strategies, including statementsregarding the potential for Aridol and/or Bronchitol. All forward-lookingstatements included in this media release are based upon information availableto us as of the date hereof, and we assume no obligation to update any suchforward-looking statement as a result of new information, future events orotherwise. We cannot guarantee that any product candidate will receive FDA orother regulatory approval or that we will seek any such approval. Factors thatcould cause or contribute to such differences include, but are not limited to,factors discussed in the "Risk Factors and Other Uncertainties" section of ourForm 20-F lodged with the U.S. Securities and Exchange Commission.For more information, please contact: Alan Robertson, Chief Executive Officer Tel: +61-2-9454-7200 Email: [email protected]
RELEASED THROUGH: Australia: Felicity Moffatt, Tel: +61-418-677-701 Email: [email protected]
United States: Brandon Lewis, Trout Group, Tel: +1-646-378-2915 Email: [email protected]
SOURCE Pharmaxis Ltd.